Krystal Biotech
NEWS
Even clinical trial announcements don’t slow down for Halloween. It was a typically busy week. Here’s a look.
Last week was a busy week for clinical trial results. Here’s a look at some of the top stories and reporting.
Exiting the last week of June and heading into July, a number of companies announced results from ongoing clinical trials. Here’s a look.
Krystal Biotech, Inc. announced positive results from its Phase 2 placebo-controlled clinical trial of KB103 (GEM-2) study and an update on results from Phase 1 (GEM-1) study.
KB105 is a new gene therapy candidate engineered with a Transglutaminase-1 (TGM1) gene construct to treat TGM1 deficient autosomal recessive congenital ichthyosis
Perhaps the biggest mover and shaker announcement this week was the unexpected resignation of Scott Gottlieb, commissioner of the U.S. Food and Drug Administration. Gottlieb will leave his post later this month to spend more time with his family.
KB103 is Krystal’s first “off-the-shelf”, topical, gene therapy candidate to treat patients suffering from Dystrophic Epidermolysis Bullosa.
JOBS
IN THE PRESS